Results 101 to 110 of about 6,429 (163)

Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model. [PDF]

Sci Rep, 2022
Abdelmoneim M, Eissa IR, Aboalela MA, Naoe Y, Matsumura S, Sibal PA, Bustos-Villalobos I, Tanaka M, Kodera Y, Kasuya H.   +9 more
europepmc   +1 more source

Development and Preliminary Application of a Droplet Digital PCR Assay for Quantifying the Oncolytic Herpes Simplex Virus Type 1 in the Clinical-Grade Production. [PDF]

Viruses, 2023
Guo M, Deng L, Liang H, Du Y, Gao W, Tian N, Bi Y, Li J, Ma T, Zhang Y, Wang H.   +10 more
europepmc   +1 more source

Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1. [PDF]

Mol Ther Oncolytics, 2023
Chouljenko DV, Murad YM, Lee IF, Delwar Z, Ding J, Liu G, Liu X, Bu X, Sun Y, Samudio I, Jia WW.   +10 more
europepmc   +1 more source

The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics. [PDF]

Mol Ther Oncolytics, 2022
Rivera-Caraballo KA, Nair M, Lee TJ, Kaur B, Yoo JY.   +4 more
europepmc   +1 more source

Reprogramming the Immunosuppressive Microenvironment in Glioblastoma Through Oncolytic Herpes Simplex Virus Therapy: A Systematic Review. [PDF]

Cells
Poboży K, Ząbek Z, Turek G, Litak J, Zhu B, Gierszon P, Litak J, Szymoniuk M, Zielińska-Turek J, Staśkiewicz G, Torres K, Ząbek M, Czyżewski W.   +12 more
europepmc   +1 more source

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma. [PDF]

Cancers (Basel), 2022
Ohnesorge PV, Berchtold S, Beil J, Haas SA, Smirnow I, Schenk A, French CA, Luong NM, Huang Y, Fehrenbacher B, Schaller M, Lauer UM.   +11 more
europepmc   +1 more source

Oncolytic Herpes Simplex Virus for Glioblastoma: Molecular Engineering, Tumor Microenvironment Barriers, and Clinical Translation. [PDF]

Curr Issues Mol Biol
Liu J, Wang Y, Gao Z, Liu T, Xu A, Li W, Li M, Song X, Guo B, Wang H, Lv W, Zhang J.   +11 more
europepmc   +1 more source

Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery. [PDF]

Mol Ther Oncol
Fu X, Benedyk T, Zhang SX.
europepmc   +1 more source

Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma. [PDF]

Nat Commun
Qin Y, Liang Z, Yu M, Lin N, Wang N, Huang X, Chen S, Peng Q, Lin Y, Wang H, Rao Y, Xu Z, Huang S, Cai J, Li Y, Zhang J, Lin C, Tan G, Xia N, Huang C.   +19 more
europepmc   +1 more source

Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook. [PDF]

Vaccines (Basel)
Zheng Y, Pei Y, Dong C, Liang J, Cai T, Zhang Y, Tan D, Wang J, He Q.   +8 more
europepmc   +1 more source